Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry

详细信息    查看全文

• 作者：Ute Amann (1) (2)
  Inge Kirchberger (1) (2)
  Margit Heier (1) (2)
  Hildegard Golüke (2)
  Wolfgang von Scheidt (3)
  Bernhard Kuch (3) (4)
  Annette Peters (2)
  Christa Meisinger (1) (2)
  
• 关键词：Acute myocardial infarction ; Mortality ; Secondary prevention drug therapy ; Drug combination
• 刊名：Clinical Research in Cardiology
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：103
• 期：8
• 页码：655-664
• 全文大小：1,039 KB
• 参考文献：1. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999-054. doi:10.1093/eurheartj/ehr236 CrossRef
  2. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA, World Heart Federation and the Preventive Cardiovascular Nurses Association (2011) AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124(22):2458-473. doi:10.1161/CIR.0b013e318235eb4d CrossRef
  3. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Bl?mstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569-619. doi:10.1093/eurheartj/ehs215 CrossRef
  4. Sackner-Bernstein J (2005) Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28(11 Suppl 1):I19–I27
  5. Gotto AM Jr, LaRosa JC (2005) The benefits of statin therapy—what questions remain? Clin Cardiol 28(11):499-03 CrossRef
  6. Vanuzzo D, Pilotto L, Pilotto L, M?h?nen M, Hobbs M, for the WHO MONICA Project (2000) Pharmacological treatment during AMI and in secondary prevention: the scientific evidence. Published by World Health Organization (WHO) and the WHO MONICA Project investigators 2000. http://www.thl.fi/publications/monica/carpfish/appenda/evidence.htm. Accessed 4 Dec 2013
  7. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task force on practice guidelines (Committee to Revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44(3):E1–E211 CrossRef
  8. Zeymer U, Junger C, Zahn R, Bauer T, Bestehorn K, Senges J, Gitt A (2011) Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. Curr Med Res Opin 27(8):1563-570. doi:10.1185/03007995.2011.590969 CrossRef
  9. Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ, DeYoung P, Fitchett DH, Langer A, Goodman SG, Canadian ACS Registries Investigators (2007) Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 154(6):1108-115 CrossRef
  10. Bauer T, Gitt AK, Jünger C, Zahn R, Koeth O, Towae F, Schwarz AK, Bestehorn K, Senges J, Zeymer U, Acute Coronary Syndromes Registry (ACOS) investigators (2010) Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabil 17(5):576-81. doi:10.1097/HJR.0b013e328338e5da CrossRef
  11. Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U (2010) The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 96(8):604-09. doi:10.1136/hrt.2009.188607 CrossRef
  12. Lahoud R, Howe M, Krishnan SM, Zacharias S, Jackson EA (2012) Effect of use of combination evidence-based medical therapy after acute coronary syndromes on long-term outcomes. Am J Cardiol 109(2):159-64. doi:10.1016/j.amjcard.2011.08.024 CrossRef
  13. Kirchmayer U, Di Martino M, Agabiti N, Bauleo L, Fusco D, Belleudi V, Arcà M, Pinnarelli L, Perucci CA, Davoli M (2013) Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: a nested case-control study in Italy. Pharmacoepidemiol Drug Saf 22(6):649-57 CrossRef
  14. Kuepper-Nybelen J, Hellmich M, Abbas S, Ihle P, Griebenow R, Schubert (2012) Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data. Eur J Clin Pharmacol 68(10):1451-460. doi:10.1007/s00228-012-1274-x CrossRef
  15. Gunnell AS, Einarsdóttir K, Sanfilippo F, Liew D, Holman CD, Briffa T (2013) Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study. Heart 99(18):1353-358. doi:10.1136/heartjnl-2013-304348 CrossRef
  16. Meisinger C, Hormann A, Heier M, Kuch B, L?wel H (2006) Admission blood glucose and adverse outcomes in non-diabetic patients with myocardial infarction in the reperfusion era. Int J Cardiol 113(2):229-35 CrossRef
  17. Kuch B, Heier M, von Scheidt W, Kling B, Hoermann A, Meisinger C (2008) 20-year trends in clinical characteristics, therapy and short-term prognosis in acute myocardial infarction according to presenting electrocardiogram: the MONICA/KORA AMI Registry (1985-004). J Intern Med 264(3):254-64. doi:10.1111/j.1365-2796.2008.01956.x CrossRef
  18. Lee JH, Yang DH, Park HS, Cho Y, Jeong MH, Kim YJ, Kim KS, Hur SH, Seong IW, Hong TJ, Cho MC, Kim CJ, Jun JE, Park WH, Chae SC, Korea Acute Myocardial Infarction Registry Investigators (2010) Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value. Am Heart J 159(6):1012-019. doi:10.1016/j.ahj.2010.03.009 CrossRef
  19. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA (2004) Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109(6):745-49 CrossRef
  20. Timoteo AT, Fiarresga A, Feliciano J, Pelicano N, Ferreira L, Oliveira JA, Serra J, Ferreira R, Quininha J (2006) Impact of combination medical therapy on mortality in patients with acute coronary syndromes. Rev Port Cardiol 25(12):1109-118
  21. Danchin N, Cambou JP, Hanania G, Kadri Z, Genès N, Lablanche JM, Blanchard D, Vaur L, Clerson P, Guéret P, USIC 2000 investigators (2005) Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 150(6):1147-153 CrossRef
  22. Gouya G, Reichardt B, Ohrenberger G, Wolzt M (2007) Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol 22(3):145-49 CrossRef
  23. Pereira M, Araujo C, Dias P, Lunet N, Subirana I, Marrugat J, Capewell S, Bennett K, Azevedo A (2013) Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study. Eur J Prev Cardiol.?doi:10.1177/2047487313494580
  24. Tuppin P, Neumann A, Danchin N, de Peretti C, Weill A, Ricordeau P, Allemand H (2010) Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 103(6-):363-75. doi:10.1016/j.acvd.2010.05.003 CrossRef
  25. Liosis S, Bauer T, Schiele R, Gohlke H, Gottwik M, Katus H, Sabin G, Zahn R, Schneider S, Rauch B, Senges J, Zeymer U (2013) Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study. Clin Res Cardiol 102(9):671-77. doi:10.1007/s00392-013-0581-2 CrossRef
  26. Sinning JM, Asdonk T, Erlh?fer C, Vasa-Nicotera M, Grube E, Nickenig G, Werner N (2013) Combination of angiographic and clinical characteristics for the prediction of clinical outcomes in elderly patients undergoing multivessel PCI. Clin Res Cardiol 102(12):865-73. doi:10.1007/s00392-013-0599-5 CrossRef
  27. Stark R, Kirchberger I, Hunger M, Heier M, Leidl R, von Scheidt W, Meisinger C, Holle R (2014) Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines. Clin Res Cardiol 103:237-45. doi:10.1007/s00392-013-0643-5
  28. Yarzebski J, Granillo E, Spencer FA, Lessard D, Gurwitz JH, Gore JM, Goldberg RJ (2009) Changing trends (1986-003) in the use of lipid lowering medication in patients hospitalized with acute myocardial infarction: a community-based perspective. Int J Cardiol 132(1):66-4. doi:10.1016/j.ijcard.2007.10.055 CrossRef
  29. Jernberg T, Johanson P, Held C, Svennblad B, Lindb?ck J, Wallentin L, SWEDEHEART/RIKS-HIA (2011) Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 305(16):1677-684. doi:10.1001/jama.2011.522 CrossRef
  30. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA, AHA/ACC, National Heart, Lung, and Blood Institute (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19):2363-372 CrossRef
  31. Milonas C, Jernberg T, Lindback J, Agewall S, Wallentin L, Stenestrand U, RIKS-HIA Group (2010) Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction. Am J Cardiol 105(9):1229-234. doi:10.1016/j.amjcard.2009.12.032 CrossRef
  32. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL, PEACE Trial Investigators (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351(20):2058-068 CrossRef
  33. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso JE, Tracy CM, Woo YJ, Zhao DX, CF/AHA Task Force (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task force on practice guidelines. Circulation 127(4):e362–e425. doi:10.1161/CIR.0b013e3182742c84 CrossRef
  34. Ewen S, Rettig-Ewen V, Mahfoud F, B?hm M, Laufs U (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 103:173-82. doi:10.1007/s00392-013-0616-8
  35. Zugck C, Franke J, Gelbrich G, Frankenstein L, Scheffold T, Pankuweit S, Duengen HD, Regitz-Zagrosek V, Pieske B, Neumann T, Rauchhaus M, Angermann CE, Katus HA, Ertl GE, St?rk S (2012) Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure. Clin Res Cardiol 101(4):263-72. doi:10.1007/s00392-011-0388-y CrossRef
  
• 作者单位：Ute Amann (1) (2)
  Inge Kirchberger (1) (2)
  Margit Heier (1) (2)
  Hildegard Golüke (2)
  Wolfgang von Scheidt (3)
  Bernhard Kuch (3) (4)
  Annette Peters (2)
  Christa Meisinger (1) (2)
  
  1. MONICA/KORA Myocardial Infarction Registry, Central Hospital of Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany
  2. Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
  3. Department of Internal Medicine I, Cardiology, Central Hospital of Augsburg, Augsburg, Germany
  4. Department of Internal Medicine/Cardiology, Hospital of N?rdlingen, N?rdlingen, Germany
  
• ISSN：1861-0692

文摘

Background Use of the four evidence-based medications [EBMs: antiplatelet agent, beta-blocker, statin and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB)] after acute myocardial infarction (AMI) has a clear impact on 1-year survival. Aim of this study was to evaluate the association between different EBM combinations at discharge and long-term survival after AMI. Methods From a German population-based AMI registry, 2,886 men and 958 women were included, aged 28-4?years, hospitalized with an incident AMI between 2000 and 2008. All data were collected by standardized interviews and chart review. All-cause mortality was assessed for all registered persons in 2010. Median follow-up time was 6.0?years (interquartile range 4.1?years). Survival analyses and multivariate Cox regression analysis were conducted. Results Of the 3,844 patients, 70.3?% were prescribed all four EBMs; 23.8?% received three, 4.6?% two, and 1.3?% were discharged with one or no EBM. Long-term survival was 71.7?% [95?% confidence interval (CI) 55.4-2.9?%], 64.7?% (95?% CI 59.2-9.6?%) and 60.2?% (95?% CI 51.9-7.5?%) in patients with four, three and Conclusions Prescribing of a combination of all four EBMs appeared to improve clinical outcomes in AMI patients by significantly reducing long-term mortality. Hospital discharge is a critical time for optimal long-term management.